Evidence of effectiveness: How much can we extrapolate from existing studies?
- 1 June 2005
- journal article
- review article
- Published by Springer Nature in The AAPS Journal
- Vol. 7 (2) , E467-E474
- https://doi.org/10.1208/aapsj070247
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Population Pharmacokinetic Analysis and Simulation of the Time‐Concentration Profile of Etanercept in Pediatric Patients With Juvenile Rheumatoid ArthritisThe Journal of Clinical Pharmacology, 2005
- Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2004
- Hypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approvalClinical Pharmacology & Therapeutics, 2003
- Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysisClinical Pharmacology & Therapeutics, 2003
- A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic modelClinical Pharmacology & Therapeutics, 2000
- Pharmacokinetic/Pharmacodynamic Modeling in Drug DevelopmentAnnual Review of Pharmacology and Toxicology, 2000
- The Pharmacokinetics of Etanercept in Healthy VolunteersAnnals of Pharmacotherapy, 2000
- Clinical Trial Simulation in Drug DevelopmentPharmaceutical Research, 2000
- Human cytokine receptorsJournal of Clinical Immunology, 1990